Which class of antidepressants is most likely prescribed for migraines?

Tricyclic Antidepressants (TCAs) are commonly prescribed for the prevention of migraines due to their efficacy in reducing the frequency and severity of migraine attacks. They work by modulating neurotransmitter levels, particularly serotonin and norepinephrine, which can help stabilize mood and reduce pain sensitivity.

Studies have demonstrated that certain TCAs, such as amitriptyline, are particularly effective in treating episodic migraines. Their use in this context is not solely due to their antidepressant properties but also because of their ability to influence pain pathways in the brain. This dual action makes TCAs a valuable option for patients who experience both migraines and depressive symptoms.

In contrast, while other classes of antidepressants, such as SSRIs and SNRIs, are effective for managing depression and anxiety, they have not been shown to be as effective in migraine prevention as TCAs. Monoamine Oxidase Inhibitors (MAOIs) are rarely used for migraines due to dietary restrictions and potential side effects. Therefore, the choice of TCAs for migraine management is well-supported in clinical practice and literature.